Cellular Signalling: A novel site comes into sight
- Chinese Academy of Sciences, China
- Keck School of Medicine of the University of Southern California, United States
The Hedgehog signalling pathway plays a central role in development and the maintenance of normal tissue function in adults. It has also been implicated in degenerative diseases and a multitude of cancers. A great deal of effort has been invested in designing drugs that target this pathway (Dellovade et al., 2006; Rubin and de Sauvage, 2006), and after more than a decade of work in both academic laboratories and pharmaceutical companies, several anticancer drugs that regulate the Hedgehog pathway have now entered the clinic. Most of these drugs target a membrane protein called Smoothened.
Now, in eLife, Rajat Rohatgi at Stanford University School of Medicine and co-workers in the US, UK and Singapore—including Sigrid Nachtergaele (Stanford) and Daniel Whalen (Oxford) as joint first authors—provide new insights into the regulation of Smoothened by oxysterols, a class of naturally occurring compounds, and suggest new options for the pharmacological modulation of Hedgehog signalling (Nachtergaele et al., 2013). Similar results have also been reported in Nature Chemical Biology by Daniel Nedelcu of Harvard Medical School and co-workers (Nedelcu et al., 2013), and in Developmental Cell by Benjamin Myers of Stanford University School of Medicine and co-workers (Myers et al., 2013).
Hedgehog signalling at the cell membrane involves two essential components: Patched1, which is a receptor for the Hedgehog signalling molecule, and Smoothened. In the absence of Hedgehog, Patched1 inhibits Smoothened. However, when Hedeghog binds to Patched1, Smoothened gets activated (Briscoe and Therond, 2013). There is now a general consensus that the interaction between Patched1 and Smoothened is mediated by a small molecule (or molecules) that is regulated by Patched1, rather than by direct physical interactions between the two (Taipale et al., 2002). This might explain why Smoothened has emerged as the most ‘druggable’ target in the Hedgehog pathway (Rubin and de Sauvage, 2006).
To date, the best candidates to emerge as the endogenous regulators of Smoothened activity are oxysterols, which are naturally occurring compounds produced through the oxidation of cholesterol (Corcoran and Scott, 2006; Dwyer et al., 2007). Of these, one of the most potent is 20(S)-hydroxycholesterol (20(S)-OHC). Previous work has shown that oxysterols modulate Smoothened in an allosteric manner; that is, in contrast to several other known modulators of this protein, oxysterols bind at a distinct site (Nachtergaele et al., 2012). The three new papers give detailed insights into the mechanism of action of oxysterol, and lend support to a model based on allosteric interactions.
Figure 1
Modulation of Smoothened in vertebrates.
The signalling molecule Hedgehog (Hh) acts via a receptor called Patched1 (Ptch1) to modulate the activity of another membrane protein called Smoothened (Smo). Activators of Smo activity are shown in red and inhibitors are shown in blue. Oxysterols (such as 20(S)-OHC) can activate Smo by binding its cysteine-rich domain (CRD), while various synthetic molecules (such as 20(R)-yne, 20-keto-yne and 22-NHC) can inhibit Smo by binding the CRD; the small molecule Smoothened agonist (SAG) can increase Smo activity by interacting with its membrane-bound region, while cyclopamine and other chemicals (shown in blue) can decrease Smo activity by interacting with this region. The endogenous small molecule(s) that mediate the inhibition of Smoothened by Patched1 remain unknown.
Smoothened shares several structural features with a family of receptors called Frizzled, which bind a signalling molecule called Wnt. In particular, both possess a cysteine-rich domain at their N-terminus. The fact that this region of Frizzled binds a palmitoyl group that is present on Wnt ligands (Janda et al., 2012) suggested that oxysterols may likewise interact with the cysteine-rich domain in Smoothened; this has now been confirmed experimentally by the latest work from the groups at Stanford and Harvard. A variety of small molecules, including clinically relevant compounds that are known to interact with a cavity embedded in the transmembrane part of the protein (Wang et al., 2013), did not compete with 20(S)-OHC for binding Smoothened. Thus, it is clear that there are separate binding events for oxysterols and these other compounds.
With the aid of the crystal structure of the cysteine-rich domain in zebrafish Smoothened, Nachtergaele et al. used computational modelling to map oxysterol binding to a hydrophobic groove on the surface of this domain. This interaction had been predicted by Myers et al. and Nedelcu et al. using in silico modelling. The cysteine-rich domain is sufficient for binding oxysterol, but this property is lost when key amino acid residues within the domain are mutated.
The initiation of Hedgehog signalling depends on Smoothened building up in a cellular structure called the primary cilium (Goetz and Anderson, 2010). The two Stanford groups and the Harvard group find that Smoothened variants with a mutated oxysterol binding site show decreased translocation to the primary cilium and decreased pathway activity in response to 20(S)-OHC. Furthermore, mutant versions of Smoothened that lack the cysteine-rich domain do not respond to 20(S)-OHC, but show a response that is similar to the response of wild-type Smoothened to molecules that interact with the transmembrane domain. Together the data provide compelling evidence that oxysterols interact with the cysteine-rich domain to modulate Smoothened activity.
These findings raise two key questions: is 20(S)-OHC the endogenous small molecule that mediates the regulation of Smoothened by Patched1? And is this the major regulatory input controlling Smoothened activity?
The mutant lacking the cysteine-rich domain exhibits a higher basal level of signalling than intact Smoothened, suggesting that the cysteine-rich domain suppresses Smoothened activity (Aanstad et al., 2009; Myers et al., 2013; Nachtergaele et al., 2013; Nedelcu et al., 2013). However, when Patched1 and the mutant version of Smoothened are expressed in cells together, the basal activity of the mutant is diminished (Myers et al., 2013). This indicates that the mutant version is still subject to regulation by Patched1. Thus the cysteine-rich domain may provide tonic control of Smoothened activity, whereas Patched1-dependent processes regulate Smoothened via a site separate from the domain. Myers et al. also discovered that a cell line that responds to Hedgehog contains no endogenous 20(S)-OHC, suggesting that this oxysterol may not be essential for the regulation of Smoothened. Moreover, the same oxysterols do not bind Smoothened in Drosophila, highlighting an evolutionary divergence in regulation of the Hedgehog pathway within the animal kingdom (Nachtergaele et al., 2013; Nedelcu et al., 2013).
Depleting sterols in cells diminishes the accumulation of Smoothened in the primary cilium, and activation of the Hedgehog pathway. The observation that the Smoothened lacking the cysteine-rich domain is still sensitive to sterol depletion suggests that these compounds may have additional roles mediated through interactions outside the domain (Myers et al., 2013). The fact that the response to Hedgehog is dampened in mutants suggests that, in vertebrates, the binding of oxysterols to the cysteine-rich domain is required for maximal activity of Smoothened (Aanstad et al., 2009; Myers et al., 2013; Nachtergaele et al., 2013; Nedelcu et al., 2013).
Naturally occurring small molecule regulators of biochemical pathways can be used to guide the development of synthetic compounds that modulate the same pathways. For example, cyclopamine, a Smoothened antagonist produced by certain plants, inspired the development of the experimental anticancer drug, saridegib (Tremblay et al., 2009). The studies discussed here reveal several oxysterol analogues that inhibit the activity of the Hedgehog pathway by competing with 20(S)-OHC for access to the cysteine-rich domain in Smoothened (Nachtergaele et al., 2013; Nedelcu et al., 2013). Two of these compounds inhibit drug-resistant variants of Smoothened found in cancer patients (Nachtergaele et al., 2013). This raises the possibility of designing next generation drugs based on a sterol scaffold, and of using treatment regimes consisting of multiple drugs to target distinct sites on the Smoothened protein.
The three new studies provide a detailed picture of the role of oxysterol in the regulation of Smoothend activity, though several important questions remain. If oxysterols are not the major regulator of Smoothened function, what is? Are there multiple modulators with distinct mechanisms that still await discovery? How does Patched1 control Smoothened? This does not appear to be via oxysterols, but is presumbly through a yet-to-be-identified major control factor (or factors). Answering these questions will open up still more possibilities for pharmacological control of the Hedgehog pathway.
References
-
The mechanisms of Hedgehog signalling and its roles in development and diseaseNature Reviews Molecular Cell Biology 14:416–429.https://doi.org/10.1038/nrm3598
-
Oxysterols stimulate Sonic hedgehog signal transduction and proliferation of medulloblastoma cellsProceedings of the National Academy of Sciences of the United States of America 103:8408–8413.https://doi.org/10.1073/pnas.0602852103
-
The hedgehog pathway and neurological disordersAnnual Review of Neuroscience 29:539–563.https://doi.org/10.1146/annurev.neuro.29.051605.112858
-
Oxysterols are novel activators of the hedgehog signaling pathway in pluripotent mesenchymal cellsJournal of Biological Chemistry 282:8959–8968.https://doi.org/10.1074/jbc.M611741200
-
The primary cilium: a signalling centre during vertebrate developmentNature Reviews Genetics 11:331–344.https://doi.org/10.1038/nrg2774
-
Oxysterols are allosteric activators of the oncoprotein SmoothenedNature Chemical Biology 8:211–220.https://doi.org/10.1038/nchembio.765
-
Oxysterol binding to the extracellular domain of Smoothened in Hedgehog signalingNature Chemical Biology 9:557–564.https://doi.org/10.1038/nchembio.1290
-
Targeting the Hedgehog pathway in cancerNature Reviews Drug Discovery 5:1026–1033.https://doi.org/10.1038/nrd2086
-
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926)Journal of Medicinal Chemistry 52:4400–4418.https://doi.org/10.1021/jm900305z
Article and author information
Author details
Publication history
- Version of Record published: December 3, 2013 (version 1)
Copyright
© 2013, Wang and McMahon
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 847
- Page views
-
- 76
- Downloads
-
- 1
- Citations
Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Cellular Signalling: A novel site comes into sight
eLife 2:e01680.
https://doi.org/10.7554/eLife.01680
Further reading
-
- Biochemistry and Chemical Biology
- Plant Biology
Metabolism and biological functions of the nitrogen-rich compound guanidine have long been neglected. The discovery of four classes of guanidine-sensing riboswitches and two pathways for guanidine degradation in bacteria hint at widespread sources of unconjugated guanidine in nature. So far, only three enzymes from a narrow range of bacteria and fungi have been shown to produce guanidine, with the ethylene-forming enzyme (EFE) as the most prominent example. Here, we show that a related class of Fe2+- and 2-oxoglutarate-dependent dioxygenases (2-ODD-C23) highly conserved among plants and algae catalyze the hydroxylation of homoarginine at the C6-position. Spontaneous decay of 6-hydroxyhomoarginine yields guanidine and 2-aminoadipate-6-semialdehyde. The latter can be reduced to pipecolate by pyrroline-5-carboxylate reductase but more likely is oxidized to aminoadipate by aldehyde dehydrogenase ALDH7B in vivo. Arabidopsis has three 2-ODD-C23 isoforms, among which Din11 is unusual because it also accepted arginine as substrate, which was not the case for the other 2-ODD-C23 isoforms from Arabidopsis or other plants. In contrast to EFE, none of the three Arabidopsis enzymes produced ethylene. Guanidine contents were typically between 10 and 20 nmol*(g fresh weight)-1 in Arabidopsis but increased to 100 or 300 nmol*(g fresh weight)-1 after homoarginine feeding or treatment with Din11-inducing methyljasmonate, respectively. In 2-ODD-C23 triple mutants, the guanidine content was strongly reduced, whereas it increased in overexpression plants. We discuss the implications of the finding of widespread guanidine-producing enzymes in photosynthetic eukaryotes as a so far underestimated branch of the bio-geochemical nitrogen cycle and propose possible functions of natural guanidine production.
-
- Biochemistry and Chemical Biology
- Medicine
Type 2 diabetes (T2D) is associated with higher fracture risk, despite normal or high bone mineral density. We reported that bone formation genes (SOST and RUNX2) and advanced glycation end-products (AGEs) were impaired in T2D. We investigated Wnt signaling regulation and its association with AGEs accumulation and bone strength in T2D from bone tissue of 15 T2D and 21 non-diabetic postmenopausal women undergoing hip arthroplasty. Bone histomorphometry revealed a trend of low mineralized volume in T2D (T2D 0.249% [0.156–0.366]) vs non-diabetic subjects 0.352% [0.269–0.454]; p=0.053, as well as reduced bone strength (T2D 21.60 MPa [13.46–30.10] vs non-diabetic subjects 76.24 MPa [26.81–132.9]; p=0.002). We also showed that gene expression of Wnt agonists LEF-1 (p=0.0136) and WNT10B (p=0.0302) were lower in T2D. Conversely, gene expression of WNT5A (p=0.0232), SOST (p<0.0001), and GSK3B (p=0.0456) were higher, while collagen (COL1A1) was lower in T2D (p=0.0482). AGEs content was associated with SOST and WNT5A (r=0.9231, p<0.0001; r=0.6751, p=0.0322), but inversely correlated with LEF-1 and COL1A1 (r=–0.7500, p=0.0255; r=–0.9762, p=0.0004). SOST was associated with glycemic control and disease duration (r=0.4846, p=0.0043; r=0.7107, p=0.00174), whereas WNT5A and GSK3B were only correlated with glycemic control (r=0.5589, p=0.0037; r=0.4901, p=0.0051). Finally, Young’s modulus was negatively correlated with SOST (r=−0.5675, p=0.0011), AXIN2 (r=−0.5523, p=0.0042), and SFRP5 (r=−0.4442, p=0.0437), while positively correlated with LEF-1 (r=0.4116, p=0.0295) and WNT10B (r=0.6697, p=0.0001). These findings suggest that Wnt signaling and AGEs could be the main determinants of bone fragility in T2D.
